NCT05915442 - Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2028

Conditions

Oligometastatic Prostate Cancer

Interventions

DRUG

Quemliclustat

100mg IV once every two weeks

DRUG

Etrumadenant

150 mg orally (PO) once a day (QD)

DRUG

Zimberelimab

240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT

RADIATION

Stereotactic Body Radiation Therapy

Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat

Trial Locations (1)

RECRUITING

Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York